{{chembox
| Watchedfields = changed
| verifiedrevid = 470610633
| ImageFile = Tiopronin.svg
| ImageFile_Ref = {{chemboximage|correct|??}}
| ImageName = Skeletal formula of tiopronin
| IUPACName = 2-(2-sulfanylpropanoylamino)acetic acid
| OtherNames = 2-mercaptopropionylglycine <br /> Acadione <br /> Thiola
|Section1={{Chembox Identifiers
| CASNo = 1953-02-2
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo1 = 29335-92-0
| CASNo1_Ref = {{cascite|correct|??}}
| CASNo1_Comment = <small>''R''</small>
| PubChem = 5483
| PubChem1 = 208825
| PubChem1_Comment = <small>''R''</small>
| PubChem2 = 736152
| PubChem2_Comment = <small>''S''</small>
| ChemSpiderID = 5283
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID1 = 180938
| ChemSpiderID1_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID1_Comment = <small>''R''</small>
| ChemSpiderID2 = 643292
| ChemSpiderID2_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID2_Comment = <small>''S''</small>
| UNII = C5W04GO61S
| UNII_Ref = {{fdacite|correct|FDA}}
| EINECS = 217-778-4
| KEGG = D01430
| KEGG_Ref = {{keggcite|correct|kegg}}
| MeSHName = Tiopronin
| ChEMBL = 1314
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| RTECS = MC0596500
| Beilstein = 1859822
| SMILES = CC(S)c(:[o]):[nH]Cc(:[o]):[oH]
| SMILES1 = CC(S)C(=O)NCC(O)=O
| StdInChI = 1S/C5H9NO3S/c1-3(10)5(9)6-2-4(7)8/h3,10H,2H2,1H3,(H,6,9)(H,7,8)
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YTGJWQPHMWSCST-UHFFFAOYSA-N
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
}}
|Section2={{Chembox Properties
| C=5 | H=9 | N=1 | S=1 | O=3
| Appearance = White, opaque crystals
| MeltingPtC = 93 to 98
| LogP = −0.674
| pKa = 3.356
| pKb = 10.641
}}
|Section6={{Chembox Pharmacology
| ATCCode_prefix = G04
| ATCCode_suffix = BX16
| ATC_Supplemental =
| Legal_US = Rx
| Pregnancy_US = C
}}
|Section7={{Chembox Hazards
| GHSPictograms = {{gHS exclamation mark}}
| GHSSignalWord = '''WARNING'''
| HPhrases = {{h-phrases|302}}
| LD50 = 1,300 mg kg<sup>−1</sup> <small>(oral, rat)</small>
}}
|Section8={{Chembox Related
| OtherFunction_label = alkanoic acids
| OtherFunction = {{unbulleted list|[[Acetylcysteine]]|[[Glycylglycine]]|[[Iminodiacetic acid]]|[[Nitrilotriacetic acid]]|[[n-Oxalylglycine|''N''-Oxalylglycine]]|[[Bucillamine]]|[[Oxalyldiaminopropionic acid]]|[[gamma-Glutamylcysteine|''gamma''-Glutamylcysteine]]}}
| OtherCompounds = {{unbulleted list|[[n-Acetylglycinamide|''N''-Acetylglycinamide]]}}
}}
}}

'''Tiopronin''' (trade name '''Thiola''') is a prescription [[thiol]] drug used to control the rate of [[cystine]] precipitation and excretion in the disease [[cystinuria]].<ref>{{cite journal|last1=Lindell|first1=Å.|last2=Denneberg|first2=T.|last3=Hellgren|first3=E.|last4=Jeppsson|first4=J. -O.|last5=Tiselius|first5=H. -G.|title=Clinical course and cystine stone formation during tiopronin treatment|journal=Urological Research|volume=23|issue=2|pages=111–117|doi=10.1007/BF00307941|year=1995}}</ref><ref>{{cite journal|last1=Coe|first1=Fredric L.|last2=Parks|first2=Joan H.|last3=Asplin|first3=John R.|title=The Pathogenesis and Treatment of Kidney Stones|journal=New England Journal of Medicine|date=15 October 1992|volume=327|issue=16|pages=1141–1152|doi=10.1056/NEJM199210153271607}}</ref> Due to the rarity of the disorder, tiopronin falls under the classification of an [[orphan drug]]. It is somewhat similar to [[penicillamine]] in both chemistry and pharmacology.

==Uses==
Tiopronin is used primarily for cystinuria and is well known in the cystinuric community. Depending on the severity of a person's cystinuria, tiopronin may be taken for life, possibly starting in early childhood. The drug works by reacting with urinary [[cysteine]] to form a more soluble, [[Disulfide bond|disulfide]] linked, tiopronin-cysteine complex.<ref name="Carlsson">{{cite journal|last1=Carlsson|first1=M. S.|last2=Denneberg|first2=T.|last3=Emanuelsson|first3=B.-M.|last4=Kågedal|first4=B.|last5=Lindgren|first5=S.|title=Pharmacokinetics of oral tiopronin|journal=European Journal of Clinical Pharmacology|date=August 1993|volume=45|issue=1|pages=79–84|doi=10.1007/BF00315354|pmid=8405034}}</ref>

It may also be used for [[Wilson's disease]] (an overload of [[copper]] in the body), and has also been investigated for the treatment of [[arthritis]],<ref>{{cite journal|last1=Delecoeuillerie|first1=G|title=[Tolerability and therapeutic maintenance of tiopronin, new basic treatment of rheumatoid arthritis. Apropos of long-term follow-up of 268 cases].|journal=Revue du rhumatisme et des maladies osteo-articulaires|date=30 April 1989|volume=56|issue=5 Pt 2|pages=38–42|pmid=2740804}}</ref><ref>{{cite journal|last1=Pasero|first1=Giampiero|last2=Pellegrini|first2=Pietro|last3=Ambanelli|first3=Umberto|last4=Ciompi|first4=Maria Laura|last5=Colamussi|first5=Vincenzo|last6=Ferraccioli|first6=Gianfranco|last7=Barbieri|first7=Paola|last8=Mazzoni|first8=Maria Rosa|last9=Menegale|first9=Germano|last10=Trippi|first10=Donatella|title=Controlled multicenter trial of tiopronin and D-penicillamine for rheumatoid arthritis|journal=Arthritis & Rheumatism|date=August 1982|volume=25|issue=8|pages=923–929|doi=10.1002/art.1780250803}}</ref> though tiopronin is not an [[anti-inflammatory]].

Tiopronin is also sometimes used as a stabilizing agent for metal [[nanoparticles]]. The thiol group binds to the nanoparticles, preventing coagulation.<ref>{{cite journal |author1=Jennifer A. Dahl |author2=Bettye L. S. Maddux |author3=James E. Hutchison  |last-author-amp=yes | title = Toward Greener Nanosynthesis | journal = Chemical Reviews | volume = 107 | issue = 6 | pages = 2228–2269 | year = 2007 | doi = 10.1021/cr050943k | pmid = 17564480}}</ref>

==Side effects==
Tiopronin may present a variety of side effects, which are broadly similar to those of [[D-penicillamine]] and other compounds containing active sulfhydryl groups.<ref>{{cite journal|last1=Jaffe|first1=Israeli A.|title=Adverse effects profile of sulfhydryl compounds in man|journal=The American Journal of Medicine|date=March 1986|volume=80|issue=3|pages=471–476|doi=10.1016/0002-9343(86)90722-9}}</ref> Its [[pharmokinetics]] have been studied.<ref name="Carlsson" />

==Costs==
In the U.S., the drug was marketed by Mission Pharmacal at $1.50 per pill, but the rights were bought by Retrophin, owned by [[Martin Shkreli]], and the price increased to $30 per pill for a 100mg capsule.<ref>{{cite web|url=http://www.fiercepharma.com/story/huge-price-hike-sales-strategy-taken-extremes-retrophin/2014-09-11|title=The huge price hike as sales strategy, taken to extremes by Retrophin|work=FiercePharma}}</ref><ref>{{cite web|url=http://www.fiercebiotech.com/story/why-would-martin-shkreli-hike-old-drug-price-5000-only-moron-would-ask/2015-09-20|title=Why would Martin Shkreli hike an old drug price by 5000%? Only a 'moron' would ask|work=FierceBiotech}}</ref><ref>{{cite web|url=http://www.rawstory.com/2015/09/pharma-bro-martin-shkreli-gouged-kids-with-kidney-disease-before-ripping-off-aids-patients/|title=‘Pharma bro’ Martin Shkreli gouged kids with kidney disease before ripping off AIDS patients|work=rawstory.com}}</ref> A potential alternative in treatment and costs has arisen with the drug 'Bucillamine'.<ref>[http://www.marketwired.com/press-release/revive-therapeutics-announces-us-fda-grants-orphan-drug-designation-bucillamine-treatment-tsx-venture-rvv-2066786.htm Market Wired Bucillamine article]</ref> There is now a low-cost alternative available from Imprimis Pharmaceuticals Inc., Tiopronin Delayed Release, at $7.68 for 100mg.<ref>{{Cite web|url=http://www.imprimisrx.com/formulation/tiopronin-delayed-release-200mg/|title=Tiopronin Delayed Release Capsules - $15.35/capsule - ImprimisRx|website=www.imprimisrx.com|access-date=2016-11-01}}</ref>

==References==
{{reflist}}

==External links==
*[http://www.thiola.com Thiola Main Site]

{{cough and cold preparations}}

[[Category:Orphan drugs]]
[[Category:Thiols]]
[[Category:Amino acid derivatives]]